Estradiol Gel (Divigel/Elestrin) FDA Approval, Label, and Compounding Legal Status

What Are Divigel and Elestrin, and When Did the FDA Approve Them?

Divigel and Elestrin are prescription transdermal gels that deliver estradiol, a bioidentical form of the primary human estrogen, through the skin. Both are approved by the FDA specifically to treat moderate-to-severe vasomotor symptoms, meaning hot flashes and night sweats, in women who are menopausal or perimenopausal.

Elestrin received FDA approval in June 2006, manufactured originally by BioSante Pharmaceuticals and now distributed under subsequent licensing agreements. Divigel was approved by the FDA in October 2006, developed by Orion Corporation and later distributed in the United States by Vertical Pharmaceuticals and Mylan. Both approvals are New Drug Applications (NDAs) backed by placebo-controlled clinical trial data in postmenopausal women.

How the Gel Is Applied

Both gels are applied once daily to clean, dry skin. Divigel is applied to the upper thigh, alternating sides. Elestrin is applied to the upper arm. Neither gel should be applied to the breast or the vaginal area. Women should let the gel dry for at least two minutes before dressing, and wash hands immediately after application to avoid transferring estradiol to other people, including children and male partners.

Doses Available

Divigel comes in unit-dose packets delivering 0.25 mg, 0.5 mg, or 1.0 mg of estradiol daily. Clinicians typically start at the lowest effective dose. Elestrin delivers 0.52 mg of estradiol per actuation of a metered-dose pump, with one pump per day as the starting dose and a maximum of two pumps daily.

What Does the FDA Prescribing Label Say?

The FDA-approved labeling for both Divigel and Elestrin follows the standard estrogen class labeling framework. The label is not a quick read, but several sections are directly relevant to what you, as a patient, need to know.

Indication: Vasomotor Symptoms Only

The approved indication is narrow: both products are indicated solely for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The label does not approve use for genitourinary syndrome of menopause (GSM), bone loss, or cardiovascular protection. If your clinician is prescribing one of these gels for GSM or osteoporosis prevention, that is off-label use, which can be appropriate but should be discussed openly.

Boxed Warning: Endometrial Cancer, Cardiovascular Events, and Breast Cancer

The label carries a black-box warning, the FDA's most serious. The warning states that estrogens increase the risk of endometrial cancer in women with a uterus who do not use a progestogen. If you have a uterus and are prescribed an estradiol gel, you need a progestogen added to your regimen, either as a separate prescription (micronized progesterone, medroxyprogesterone acetate) or as a combined product. This is non-negotiable from a safety standpoint.

The boxed warning also references increased risks of cardiovascular events, stroke, and breast cancer drawn from the Women's Health Initiative (WHI) trials, which studied conjugated equine estrogen, not transdermal estradiol. The Menopause Society notes explicitly that WHI findings should not be extrapolated directly to transdermal estradiol formulations, and that the risk profile may differ by route of administration.

Contraindications Listed on the Label

The label lists absolute contraindications:

• Undiagnosed abnormal uterine bleeding
• Known, suspected, or history of breast cancer
• Known or suspected estrogen-dependent neoplasia
• Active DVT, pulmonary embolism, or a history of these conditions
• Active arterial thromboembolic disease (stroke, MI)
• Known thrombophilic disorders (e.g., protein C, protein S, or antithrombin deficiency)
• Liver dysfunction or disease
• Pregnancy (Category X)
• Known hypersensitivity to the product

Compounding Legal Status: Can a Pharmacy Make a Compounded Version?

This is where the regulatory picture gets specific, and many women are confused. The short answer: compounding pharmacies face significant federal restrictions on making copies of Divigel or Elestrin.

The FDA Demonstrably Difficult to Compound List

Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, a pharmacy may not compound a drug that is "essentially a copy" of an FDA-approved product, unless the drug is on the FDA's list of drugs that are demonstrably difficult to compound. Estradiol gels, including formulations comparable to Divigel and Elestrin, appear on FDA guidance documents governing compounding of hormone therapies, and the FDA has consistently maintained that transdermal estradiol gels are not appropriate for routine compounding because FDA-approved alternatives exist.

The framework works like this: a 503A compounding pharmacy (a traditional pharmacy compounding for individual patients with a prescription) may compound a transdermal estradiol preparation only if there is a documented clinical difference from the commercially available product, such as an allergy to an inactive ingredient, a dose not available commercially, or a documented clinical need that the approved product cannot meet. Simply being cheaper or more convenient does not satisfy this standard.

A 503B outsourcing facility (a larger compounder that may sell to hospitals or clinics without patient-specific prescriptions) faces even stricter rules. Estradiol is not on the FDA's 503B bulk drug substances list as an approved bulk substance for that pathway when approved finished products exist.

Why This Matters for You

Women sometimes seek compounded estradiol gel because it appears cheaper, is marketed as "natural" or "bioidentical," or is promoted by certain clinics as superior. The evidence does not support that compounded preparations are more effective or safer than FDA-approved transdermal estradiol, which is itself bioidentical, meaning it has the same molecular structure as the estradiol your ovaries produced. The difference is that FDA-approved products have been tested for dose consistency, absorption, and manufacturing quality. Compounded preparations have not passed the same standardized tests, and the FDA has documented dose variability and contamination problems in compounded hormone preparations in its surveillance work.

If a telehealth or compounding pharmacy offers you a compounded estradiol gel as routine practice without a documented clinical reason, that provider may be operating outside federal guidelines.

Transdermal vs. Oral Estrogen: The Safety Difference That Matters Most

For many women in perimenopause and menopause, the route of estrogen delivery is clinically significant, not a minor packaging detail.

VTE Risk: Why the Transdermal Route Is Preferred for Higher-Risk Women

Oral estrogens undergo first-pass metabolism in the liver, which amplifies procoagulant factor production and raises venous thromboembolism (VTE) risk. Transdermal estradiol bypasses this first-pass effect. A 2019 meta-analysis in The New England Journal of Medicine context, and specifically the large case-control study published in BMJ by Vinogradova et al., found that transdermal estradiol was not associated with increased VTE risk, while oral estrogen was, with an odds ratio of approximately 2.0 for oral preparations compared to non-use.

This distinction matters most if you have a personal or family history of DVT or pulmonary embolism, carry a factor V Leiden or prothrombin gene mutation, have a BMI >30, smoke, or are immobile for prolonged periods. For these women, transdermal estradiol gel is the preferred formulation when hormone therapy is being considered.

Migraine and Estrogen Fluctuation

Women who have migraine with aura have an elevated stroke risk with combined oral contraceptives. Transdermal estradiol produces a steadier serum level than oral preparations, which may reduce hormonally triggered migraine attacks in perimenopausal women. This has not been tested in the key Divigel or Elestrin trials specifically, but is supported by mechanistic data and is reflected in clinical practice guidelines from ACOG.

Metabolic Effects Across Life Stage

In the perimenopausal years, as ovarian function declines, estrogen levels fluctuate unpredictably. The steady transdermal delivery of Divigel or Elestrin can smooth these fluctuations. In postmenopausal women, the metabolic benefits of transdermal estradiol on insulin sensitivity and lipid profiles differ from oral estrogen in ways that are clinically meaningful for women with PCOS history, metabolic syndrome, or elevated triglycerides. Oral estrogens raise triglycerides; transdermal estradiol does not, or raises them substantially less. ACOG's clinical guidance on menopausal symptom management acknowledges the route-dependent differences in metabolic and thrombotic risk.

Pregnancy, Lactation, and Contraception: Required Reading

Estradiol gel is contraindicated in pregnancy. This is a firm regulatory and clinical position. Both Divigel and Elestrin carry an FDA Pregnancy Category X designation, meaning that animal and human data demonstrate fetal risk that outweighs any possible benefit.

Pregnancy

The FDA label for both products explicitly states that estrogens should not be used during pregnancy. Prenatal estrogen exposure has been associated with congenital reproductive tract abnormalities. If you are using an estradiol gel and are not postmenopausal, you must use reliable contraception. The clinical scenario where this matters: perimenopausal women who are still ovulating sporadically. Perimenopause does not reliably prevent conception. Women in early perimenopause, particularly those under 51 with irregular cycles, should use contraception simultaneously with estradiol gel therapy.

Lactation

Estradiol passes into breast milk. Postmenopausal women are not lactating, so this does not usually arise in the typical Divigel or Elestrin patient. However, for any woman who is lactating, estradiol gel should not be used. Beyond direct transfer into milk, systemic estrogen can suppress prolactin and reduce milk supply. The NIH LactMed database notes that systemic estrogen use is generally discouraged during breastfeeding.

Contraception Requirements for Perimenopausal Users

If you are perimenopausal and your clinician has prescribed an estradiol gel for symptom management, discuss contraception explicitly at that appointment. Low-dose combined hormonal contraceptives, the levonorgestrel IUD, or progestogen-only methods are all compatible with perimenopause management and provide contraception simultaneously. Do not assume that hot flashes mean ovulation has stopped.

Female-Specific Conditions: PCOS, Thyroid, and Hormonal Interactions

PCOS and Insulin Resistance

Women with a history of PCOS who reach perimenopause carry a higher baseline metabolic risk. Transdermal estradiol does not worsen insulin resistance the way oral conjugated estrogens may, making Divigel or Elestrin a preferable route for this group. The evidence here is mechanistic and observational rather than from dedicated RCTs in PCOS populations, a gap that should be stated plainly.

Thyroid Hormone and Estradiol Gel

Oral estrogens increase thyroid-binding globulin (TBG) and can raise the total T4 level, potentially requiring upward adjustment of levothyroxine doses in women with hypothyroidism. Transdermal estradiol has a substantially smaller effect on TBG. This pharmacokinetic difference is well-documented and means women with hypothyroidism who switch from oral to transdermal estrogen may need thyroid function re-checked at 6 to 8 weeks after the switch, though their levothyroxine dose is less likely to need adjustment than it would be with an oral product.

Female Pattern Hair Loss

Estrogen supports the anagen phase of the hair cycle. As estrogen declines in perimenopause and menopause, female pattern hair loss accelerates in some women. Systemic estradiol gel does not carry an FDA approval for hair loss treatment, and evidence is limited. A clinician who prescribes it specifically for hair loss is doing so off-label.

Genitourinary Syndrome of Menopause (GSM)

Divigel and Elestrin treat vasomotor symptoms. They are not the first-line treatment for GSM (vaginal dryness, urinary urgency, dyspareunia). For GSM, local vaginal estrogen products, such as Vagifem, Imvexxy, or Premarin cream, deliver estradiol or conjugated estrogen directly to tissue with minimal systemic absorption, and are the preferred approach. Systemic estradiol gel may improve GSM symptoms as a secondary benefit, but should not replace local therapy when GSM is the primary complaint.

Who This Is Right For, and Who Should Look at Other Options

Women Who Are Good Candidates for Estradiol Gel

• Postmenopausal women with moderate-to-severe hot flashes or night sweats
• Perimenopausal women with symptomatic vasomotor symptoms who are using reliable contraception
• Women who have a contraindication to oral estrogen due to elevated VTE risk, elevated triglycerides, or migraine with aura
• Women with hypothyroidism on levothyroxine who want to avoid TBG-driven thyroid fluctuation
• Women with a PCOS history who are concerned about worsening insulin resistance with oral estrogen

Women for Whom Estradiol Gel Is Not Appropriate

• Women who are pregnant or may be pregnant (Category X, contraindicated)
• Women who are breastfeeding
• Women with active or prior estrogen-receptor-positive breast cancer
• Women with active DVT, PE, stroke, or MI
• Women with undiagnosed abnormal uterine bleeding
• Women with known thrombophilic disorders where even transdermal estrogen has uncertain safety

The Uterus Question: Do You Need a Progestogen?

If you have a uterus, you need a progestogen added to any systemic estrogen therapy. This applies to estradiol gel. The risk of endometrial hyperplasia and cancer from unopposed estrogen is not theoretical: the risk of endometrial cancer with unopposed oral estrogen use for over 10 years rises to approximately 10 times that of non-users. Transdermal estradiol carries the same endometrial risk as oral preparations unless a progestogen is co-prescribed. Women who have had a hysterectomy do not need a progestogen.

Post-Market Safety Surveillance and What It Shows

Since approval in 2006, both Divigel and Elestrin have accumulated nearly two decades of real-world use data. No new safety signals specific to the gel formulation have emerged that are not already reflected in the class labeling for estrogens.

The most clinically meaningful post-approval data for transdermal estradiol specifically relates to VTE. The Vinogradova et al. Case-control study (BMJ, 2019), drawing on UK Clinical Practice Research Datalink data with over 80,000 women, confirmed that transdermal estradiol was not associated with increased VTE risk at doses up to 50 mcg/day, unlike oral estrogens. Divigel at its 1.0 mg dose delivers approximately 50 mcg/day, so this finding is directly applicable.

The FDA Sentinel System, which monitors real-world adverse events in insured US patients, has not generated a safety alert specific to estradiol transdermal gels as a class since their approval. The long-term endometrial and breast cancer surveillance data for transdermal estradiol remains less complete than for oral conjugated estrogens studied in WHI, a genuine evidence gap that clinicians and patients should acknowledge.

As WomanRx medical reviewer Dr. Elena Vasquez notes: "The regulatory status of compounded estradiol gels is one of the most commonly misunderstood points in menopausal care. FDA-approved transdermal estradiol is itself bioidentical. When a patient is offered a compounded version without a documented clinical rationale, they are accepting unknown dose variability in exchange for no proven benefit."

Practical Steps Before Starting Estradiol Gel

1. Confirm your uterine status. If you have a uterus, your prescriber must add a progestogen. Ask for the specific progestogen, the dose, and the schedule before filling the estradiol gel prescription.
2. Discuss your VTE history and thrombophilia risk. If you have had a DVT or carry a clotting disorder, transdermal is likely the safer choice over oral, but confirm with your clinician.
3. Ask whether the prescription is for Divigel or Elestrin specifically. If a compounded estradiol gel is offered, ask for the documented clinical reason that the FDA-approved product cannot be used.
4. If you are perimenopausal and still having periods, arrange reliable contraception before starting.
5. Check your thyroid medication. If you take levothyroxine, request a TSH recheck 6 to 8 weeks after starting or switching to an estradiol gel.
6. Transfer care if needed. If your current provider is prescribing compounded estradiol without medical justification, a telehealth menopause specialist can review whether an FDA-approved formulation is appropriate.